Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc. is positioned favorably with its innovative ADI-001 therapy showing significant efficacy in lupus nephritis and systemic lupus erythematosus, indicating strong potential in treating autoimmune diseases alongside oncology targets. The initiation of a Phase 1 study for ADI-212 in metastatic castration-resistant prostate cancer in 2026, with data expected later that year, suggests upcoming value inflection points that could enhance the company's growth trajectory. Additionally, the plan to utilize third-party manufacturers for commercial-scale production is expected to mitigate manufacturing risks, supporting a more reliable path to market for their therapies.

Bears say

Adicet Bio Inc. faces significant financial challenges, projecting a net loss of $1.13 per share for 2025, indicating concerns about its profitability. The company’s pipeline, particularly the ADI-001 candidate, may suffer from lower-than-expected efficacy and increased regulatory risks, as no FDA-approved therapies exist for Vδ1 gamma-delta T cells, contributing to a cautious outlook. Additionally, potential setbacks in clinical development, competition affecting market share, and long-term dilution risks further exacerbate the negative financial projections for Adicet Bio's stock.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.